Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 6/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 3/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL411031 | 1.00 | MAP4K4 (0.44) | MAP4K4PTGDR2KMORORCPTGS2 | |
| SCHEMBL411019 | 0.81 | MAP4K4 (0.38) | MAP4K4PTGDR2KMORORCPTGS2 | |
| SCHEMBL440826 | 0.80 | PTGDR2 (0.50) | MAP4K4PTGDR2KMOCNR2 | |
| SCHEMBL411891 | 0.78 | MAP4K4 (0.49) | MAP4K4PTGDR2KMOPTGS2CNR2 | |
| SCHEMBL411573 | 0.77 | NPC1 (0.45) | CNR2 | |
| SCHEMBL444341 | 0.77 | NPC1 (0.45) | CNR2 | |
| SCHEMBL411490 | 0.77 | KMO (0.41) | KMORORCDHODHGABRA5P2RX3 | |
| SCHEMBL439869 | 0.77 | CNR1 (0.48) | MAP4K4PTGS2 | |
| SCHEMBL410515 | 0.77 | CNR1 (0.48) | MAP4K4PTGS2 | |
| SCHEMBL439158 | 0.77 | KMO (0.41) | KMORORCDHODHGABRA5P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2613785-B1 | HETEROARYLMETHYL AMIDES | HOFFMANN LA ROCHE (CH) | 2015-07-29 | — | — | EP | disclosed |
| US-9090599-B2 | Heteroarylmethyl amides | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2651895-B1 | OXIME COMPOUNDS AS HDL-CHOLESTEROL RAISING AGENTS | HOFFMANN LA ROCHE (CH) | 2015-07-01 | — | — | EP | disclosed |
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | HOFFMANN-LA ROCHE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8729105-B2 | Heteroarylmethyl amides | HOFFMANN LA-ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8669254-B2 | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents | HOFFMAN-LA ROCHE INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20120157476-A1 | OXIME COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | MAP4K4 4374/4885PTGDR2 2386/4885KMO 2423/4885 |
| US-20120157476-A1 | OXIME COMPOUNDS | APOB, APOL1, PON1 | MAP4K4 3549/4885PTGDR2 854/4885KMO 1057/4885 |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | MAP4K4 4374/4885PTGDR2 2386/4885KMO 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.